Register entry
Ardelyx, Inc.
- Registered sites
- 0
- Drug products
- 4
- Live patents
- 24
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
24Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| IBSRELA | TENAPANOR HYDROCHLORIDE | Dec 2029 |
| IBSRELA | TENAPANOR HYDROCHLORIDE | May 2030 |
| IBSRELA | TENAPANOR HYDROCHLORIDE | Aug 2033 |
| IBSRELA | TENAPANOR HYDROCHLORIDE | Nov 2042 |
| XPHOZAH | TENAPANOR HYDROCHLORIDE | Dec 2029 |
| XPHOZAH | TENAPANOR HYDROCHLORIDE | Aug 2033 |
| XPHOZAH | TENAPANOR HYDROCHLORIDE | Apr 2034 |
| XPHOZAH | TENAPANOR HYDROCHLORIDE | Nov 2042 |
Catalogue
Marketed products
4Showing 4 of 4.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| IBSRELA | tenapanor hydrochloride | TABLET | NDA |
| XPHOZAH 10 mg | Tenapanor | TABLET, FILM COATED | NDA |
| XPHOZAH 20 mg | Tenapanor | TABLET, FILM COATED | NDA |
| XPHOZAH 30 mg | Tenapanor | TABLET, FILM COATED | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.